DKK1,321.00
2.01%
Copenhagen, May 16, 04:59 pm CET
ISIN
DK0010272202
Symbol
GMAB
Sector

Genmab A/S Stock price

DKK1,321.00
+29.50 2.28% 1M
-142.50 9.74% 6M
-171.50 11.49% YTD
-705.00 34.80% 1Y
-788.00 37.36% 3Y
-692.00 34.38% 5Y
+759.50 135.26% 10Y
Copenhagen, Closing price Fri, May 16 2025
+26.00 2.01%
ISIN
DK0010272202
Symbol
GMAB
Sector

Key metrics

Market capitalization DKK81.21b
Enterprise Value DKK59.91b
P/E (TTM) P/E ratio 10.65
EV/FCF (TTM) EV/FCF 7.44
EV/Sales (TTM) EV/Sales 2.67
P/S ratio (TTM) P/S ratio 3.62
P/B ratio (TTM) P/B ratio 2.30
Revenue growth (TTM) Revenue growth 26.39%
Revenue (TTM) Revenue DKK22.45b
EBIT (operating result TTM) EBIT DKK7.46b
Free Cash Flow (TTM) Free Cash Flow DKK8.05b
Cash position DKK22.28b
EPS (TTM) EPS DKK122.77
P/E forward 12.85
P/S forward 3.34
EV/Sales forward 2.46
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Genmab A/S forecast:

19x Buy
70%
7x Hold
26%
1x Sell
4%

Analyst Opinions

27 Analysts have issued a Genmab A/S forecast:

Buy
70%
Hold
26%
Sell
4%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
22,451 22,451
26% 26%
100%
- Direct Costs 1,098 1,098
-
5%
21,353 21,353
-
95%
- Selling and Administrative Expenses 3,901 3,901
12% 12%
17%
- Research and Development Expense 9,994 9,994
22% 22%
45%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 7,459 7,459
31% 31%
33%
Net Profit 7,901 7,901
45% 45%
35%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today